Paper
2021.02.08
Publication of a preclinical study: chronic exposure to SCO-267, a GPR40, is effective in treating diabetes in preclinical models
Paper
2020.12.23
Publication of a preclinical study: the enteropeptidase inhibitor SCO-792 is therapeutically effective for improving renal function in a nondiabetic rat model of chronic kidney disease
Paper
2020.12.07
Publication of a preclinical study: SCO-792, an enteropeptidase inhibitor, improves obesity via microbiota-driven mechanisms in mice
Publication
2020.09.15
Conference presentation regarding medicinal chemistry research on a GPR40 full agonist (SCO-267)
Publication
2020.09.10
Publication regarding medicinal chemistry research on a GPR40 full agonist (SCO-267)
Publication
2020.09.08
Publication of a preclinical study: SCO-792, an enteropeptidase inhibitor, may be a new therapeutic agent for diabetic kidney disease
Business
2020.08.11
SCOHIA initiates a phase 1 study on a dual GLP-1 and GIP receptor agonist (SCO-094)
Publication
2020.07.28
Publication regarding a preclinical study; SCO-267, a GPR40 full agonist, is a novel strategy to treat NAFLD
Business
2020.06.24
SCOHIA initiates a phase 2 proof of concept study on an enteropeptidase inhibitor (SCO-792) for diabetic kidney disease
Business
2020.05.28
Pipeline Information has been updated.
Page Top